Extrait

To evaluate the anti-tumor activity of MSC1936369B combined with gemcitabine compared to gemcitabine alone as first line treatment in subjects with metastatic pancreatic adenocarcinoma. During the safety run-in the Maximum Tolerated Dose (MTD) and the recommended dose of MSC1936369B when combined with gemcitabine in subjects with metastatic pancreatic adenocarcinoma will be determined for each of the two treatment regimens.

Critère d'inclusion

• First line treatment of metastatic pancreas CA with MSC1936369B in combination with gemcitabine and / or after progression under gemcitabine monotherapy second line treatment with MSC1936369B

Liens

• ictrp
• ictrp
• ictrp
• euctr
• euctr
• euctr
• ictrp
• ictrp
• euctr
• euctr